V9, Ms

Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG1/k
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Cytoplasmic
Kontrolle:Tonsil, lymp node
Synonyme:FLJ36605, OTTHUMP00000019224, VIM, Vimentin.
Verfügbar in folgenden Ländern:worldwide

Vimentin is a type III intermediate filament (IF) protein and part of the cytoskeleton structure. The protein is expressed in mesenchymal cells and in a variety of tumors and cultured cells. It is also expressed in many cells during development. Vimentin plays an important role of cytoskeletal stability and cell integrity. During Mitosos Vimentin is phosphorylated by several kinases like Auroa B, Rho-kinases or Cdk1. The antibody is a marker of mesenchymal cells. It can be used in combination with a panel of antibodies to detect tumors with mesenchymal origin and malignant melanoma.


[1] Ben-ZeÍev A (1984): Differential control of cytokeratins and vimentin synthesis by cell- cell contact and cell spreading in cultured epithelial cells. J Cell Biol. 99(4): 1424Ð1433.
[2] Battifora H (1991): Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol. 96(5):669-71.
[3] Goto H, Tanabe K, Manser E et al. (2002): Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK). Genes Cells. 7(2):91-7.
[4] Yamaguchi T, Goto H, Yokoyama T et al. (2005): Phosphorylation by Cdk1 induces Plk1-mediated vimentin phosphorylation during mitosis. JCB. 171 (3): 431.
[5] Kruslin B, Kopjar A, Dimanovski J et al. (1999): Correlation between vimentin expression and morphological features of renal cell carcinoma. Acta Med Croatica. 53(1):11-4.
[6] Furuse C, Cury PR, de Araœjo NS et al. (2006): Application of two different clones of vimentin to the diagnosis of salivary gland tumors. 14(2):217-9. Appl Immunohistochem Mol Morphol.
[7] Goel, NM Rao, V Santhi et al. (2018): Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to Cytokeratin and Vimentin. Iran J Pathol. 13(1): 23-29.